2013
DOI: 10.1369/0022155413484152
|View full text |Cite
|
Sign up to set email alerts
|

Technologies for Investigating the Physiological Barriers to Efficient Lipid Nanoparticle–siRNA Delivery

Abstract: Small interfering RNA (siRNA) therapeutics have advanced from bench to clinical trials in recent years, along with new tools developed to enable detection of siRNA delivered at the organ, cell, and subcellular levels. Preclinical models of siRNA delivery have benefitted from methodologies such as stem-loop quantitative polymerase chain reaction, histological in situ immunofluorescent staining, endosomal escape assay, and RNA-induced silencing complex loading assay. These technologies have accelerated the detec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
16
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(17 citation statements)
references
References 137 publications
1
16
0
Order By: Relevance
“…This can be reinforced by the fact that over 85% of the delivered dextran was detected in the vesicles that also contained HRP 5 min after both were simultaneously introduced to cells ( Figure 5B). Both dextran and HRP are similar types of pinocytic endocytosis markers that readily enter cells through multiple pathways [60][61][62]. Nanoparticles formed of cationic polymers, however, are more likely to enter cells through a more specific pathway [63].…”
Section: Discussionmentioning
confidence: 99%
“…This can be reinforced by the fact that over 85% of the delivered dextran was detected in the vesicles that also contained HRP 5 min after both were simultaneously introduced to cells ( Figure 5B). Both dextran and HRP are similar types of pinocytic endocytosis markers that readily enter cells through multiple pathways [60][61][62]. Nanoparticles formed of cationic polymers, however, are more likely to enter cells through a more specific pathway [63].…”
Section: Discussionmentioning
confidence: 99%
“…Clinical development of small interfering RNA (siRNA)-based therapeutics outside liver has been limited primarily by poor bioavailability to extra-hepatic tissues and cell types of interest. When delivered systemically, siRNA formulated within a lipid nanoparticle or carrying a hepatocyte-specific targeting ligand can trigger near-complete and highly specific mRNA silencing of numerous targets in the liver at well-tolerated doses 2, 3, 4. For certain indications, local delivery of siRNA (e.g., mucosal, intraocular, intrathecal) may be more desirable than the standard intravenous or subcutaneous administration, as it may enable higher oligonucleotide concentrations in relevant tissues and protection from systemic nucleases 5, 6.…”
Section: Introductionmentioning
confidence: 99%
“…159 The efficiency of therapeutic interfering RNAs can be evaluated through biodistribution, cellular and subcellular localization studies, endosomal escape efficiency and RISC-loading efficacy studies. 160…”
Section: ■ Challenges In Delivering Rnasmentioning
confidence: 99%